MedPath

Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease

Completed
Conditions
Peyronie's Disease
Interventions
Drug: Subjects Previously Treated with AA4500
Registration Number
NCT02298829
Lead Sponsor
Endo Pharmaceuticals
Brief Summary

This a Phase 4 non-treatment, long-term follow-up study of subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc. After participation in one of the aforementioned studies, subjects will be followed yearly for up to 4 consecutive long-term follow-up visits with at least 6 months between consecutive visits

Detailed Description

At each long-term follow-up visit, subjects will be assessed for adverse events relative to their previous long-term follow-up assessment. Blood samples for the determination of antibodies to AUX-I and AUX-II and neutralizing antibodies to AUX-I and AUX-II will be collected at each long-term follow-up visit.

At each long-term follow-up visit, a flaccid penile examination will be performed and a curvature deformity measurement (with the penis in the erect state) will be recorded. Subjects will also be asked to complete the Peyronie's Disease Questionnaire (PDQ) and the International Index of Erectile Function (IIEF) questionnaire. At each visit, medical, surgical, or other treatments for Peyronie's disease since the last assessment will also be collected and recorded.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
184
Inclusion Criteria
  1. Have received at least one injection of AA4500 and completed at least the first or last follow-up visit in one of the Auxilium-sponsored studies (AUX CC-802, AUX-CC-803, AUX-CC-804, or AUX-CC-806).

  2. Be able and willing to comply with the follow-up assessments outlined in the protocol, as determined by the investigator.

  3. Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).

Exclusion Criteria

None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
No TreatmentSubjects Previously Treated with AA4500Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
Primary Outcome Measures
NameTimeMethod
To assess the long-term safety of AA4500 in adult men with Peyronies disease5 years post treatment
Secondary Outcome Measures
NameTimeMethod
To characterize curvature deformity over time in adult men with Peyronies disease who were treated with AA45005 years post treatment

Trial Locations

Locations (29)

South Florida Medical Research

🇺🇸

Aventura, Florida, United States

Bruce R. Gilbert, MD, PhD, PC

🇺🇸

Great Neck, New York, United States

Uropartners, LLC

🇺🇸

Chicago, Illinois, United States

Men's Health Boston

🇺🇸

Chestnut Hill, Massachusetts, United States

Metropolitan Urology P.S.C

🇺🇸

Jefferson, Indiana, United States

Jean Brown Research

🇺🇸

Salt Lake City, Utah, United States

Urology Assoc Medical Group

🇺🇸

Burbank, California, United States

South Orange County Med Research Center

🇺🇸

Laguna Hills, California, United States

Georgis Patsias, M.D., PA

🇺🇸

Wellington, Florida, United States

Idaho Urologic Institute

🇺🇸

Meridian, Idaho, United States

Urology of Indiana LLC

🇺🇸

Avon, Indiana, United States

Manhattan Medical Research Practice PLLC

🇺🇸

New York, New York, United States

Kansas City Urology Care, PA

🇺🇸

Overland Park, Kansas, United States

Michael A. Werner, MD PC

🇺🇸

Purchase, New York, United States

Center for Male Reproductive Medicine

🇺🇸

Hackensack, New Jersey, United States

Community Care Physicians, PC

🇺🇸

Albany, New York, United States

Florida Urology Associates

🇺🇸

Orlando, Florida, United States

Alaska Clinical Research Center, LLC

🇺🇸

Anchorage, Alaska, United States

The Urology Center of Colorado

🇺🇸

Denver, Colorado, United States

Dupage Medical Group

🇺🇸

Winfield, Illinois, United States

Premier Urology Assoc LLC dba AdvanceMed Research

🇺🇸

Lawrenceville, New Jersey, United States

San Diego Sexual Medicine

🇺🇸

San Diego, California, United States

Chesapeake Urology Research Associates

🇺🇸

Towson, Maryland, United States

Tristate Urologic Services dba TUG Research

🇺🇸

Cincinnati, Ohio, United States

Urology Clinics of North Texas, PA

🇺🇸

Dallas, Texas, United States

Urology of Virginia, PLLC

🇺🇸

Virginia Beach, Virginia, United States

Urologic Consultants of SE PA

🇺🇸

Bala-Cynwyd, Pennsylvania, United States

Associated Urologists of North Carolina

🇺🇸

Raleigh, North Carolina, United States

Virginia Urology

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath